Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Breast Cancer
Phase PHASE3
Enrollment 446
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer after failure of prior endocrine therapy.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BL-B01D1 — Administration by intravenous infusion for a cycle of 3 weeks.
  • Drug: Albumin-Bound Paclitaxel — Administration by intravenous infusion for a cycle of 4 weeks.
  • Drug: Paclitaxel — Administration by intravenous infusion for a cycle of 3 weeks.
  • Drug: Capecitabine — Oral administration for a cycle of 3 weeks.

Primary Outcomes

  • Progression-free survival (PFS) (Up to approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-07-06
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 446 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Sa Xiao, PHD
15013238943
xiaosa@baili-pharm.com
Binghei Xu
Cancer Hospital Chinese Academy of Medical Sciences
Interventions
  • Drug: BL-B01D1 — Administration by intravenous infusion for a cycle of 3 weeks.
  • Drug: Albumin-Bound Paclitaxel — Administration by intravenous infusion for a cycle of 4 weeks.
  • Drug: Paclitaxel — Administration by intravenous infusion for a cycle of 3 weeks.
  • Drug: Capecitabine — Oral administration for a cycle of 3 weeks.
Study Locations (1 sites)
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality China
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily sign the informed consent form and comply with the protocol requirements; 2. No gender restrictions; 3. Age ≥ 18 years; 4. Expected survival time ≥ 3 months; 5. Patients with unresectable locally advanced, recurrent, or metastatic HR+ HER2- breast cancer; 6. Trial participants have not received systemic chemotherapy; 7. Trial participants have progressed after at least one line of endocrine therapy, etc.; 8. Documented radiographic disease progression prior to enrollment; 9. Agree to provide archived tumor tissue specimens or fresh tissue samples from the primary or metastatic lesion within 3 years; 10. Must have at least one measurable lesion as defined by RECIST v1.1; 11. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 12. Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0; 13. No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥ 50%; 14. Must meet required organ function levels; 15. Urinary protein ≤ 2+ or \< 1000 mg/24h; 16. For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, with a negative serum pregnancy result, and they must not be breastfeeding; all enrolled patients (regardless of gender) must use adequate barrier contraception throughout the treatment period and for 6 months after treatment ends. Exclusion Criteria: 1. Previously treated with ADC drugs that use topoisomerase I inhibitors as the toxin or target EGFR and/or HER3; 2. Use of chemotherapy, biotherapy, immunotherapy, etc., within 4 weeks or 5 half-lives before the first dose; 3. Previous treatment with anthracycline drugs where the equivalent cumulative dose of doxorubicin exceeds 360 mg/m²; 4. History of severe cardiovascular or cerebrovascular diseases; 5. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; 6. Prolonged QT interval, complete left bundle branch block, etc.; 7. Diagnosis of another malignancy within 3 years before the first dose; 8. Hypertension poorly controlled by two antihypertensive medications; 9. Poorly controlled blood glucose levels; 10. History of ILD requiring steroid therapy, current ILD, or grade ≥2 radiation pneumonitis, etc.; 11. Concurrent pulmonary diseases causing clinically severe respiratory function impairment; 12. Patients with active central nervous system metastases; 13. Presence of large serous cavity effusions or symptomatic serous cavity effusions, etc.; 14. Imaging findings indicating tumor invasion or encasement of the abdomen, chest, etc.; 15. Severe infection within 4 weeks before study randomization; 16. Severe, unhealed wounds, ulcers, or fractures within 4 weeks before signing the informed consent form; 17. Trial participants with clinically significant bleeding or a significant bleeding tendency within 4 weeks prior to signing the informed consent form; 18. History of inflammatory bowel disease, extensive bowel resection, etc.; 19. Patients with a history of allergy to recombinant humanized antibodies or allergy to BL-B01D1 or any of its excipients; 20. History of autologous or allogeneic stem cell transplantation; 21. Positive for human immunodeficiency virus antibodies, active hepatitis B virus infection, or hepatitis C virus infection; 22. Receipt of other unapproved clinical study drugs or treatments within 4 weeks before the first dose; 23. Trial participants planning to receive or having received live vaccines within 28 days before the first dose; 24. Other conditions deemed by the investigator to be unsuitable for participation in this clinical trial due to complications or other reasons.
Conditions Breast Cancer (Locally Advanced or Metas...
Phase PHASE1, PHASE2
Enrollment 201
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-6452 in adult patients with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) advanced/metastatic breast cancer or locally advanced/metastatic solid tumor.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: INV-6452 — once daily orally

Primary Outcomes

  • Phase 1: Maximum tolerated dose (MTD) (Within first 28 days of treatment)
  • Phase 1: Recommended dose range (RDR) (12 months)
  • Phase 2: Evaluate overall response rate (ORR) (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-07-04
Completion: 2028-02-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 201 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.
Contact Information
Study Contact:
Yi Zhu, MD, MBA
1 908 240 7514
yi.zhu@ionovabio.com
Jiong Wu, MD
021-6417 5590
wujiong1122@vip.sina.com
Fudan University Shanghai Cancer Center
Jiong Wu, MD
Fudan University Shanghai Cancer Center
Interventions
  • Drug: INV-6452 — once daily orally
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality China
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent obtained. 2. Adult patients aged ≥ 18 years. 3. Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors, who have disease progression following standard-of-care therapy, are intolerant to standard treatment, or have no available standard treatment options (e.g., HR+/HER2- breast cancer, Cyclin E1-overexpressing solid tumors and other solid tumors). 4. Agree to provide available archived FFPE tumor tissue specimens or voluntarily accept pre-treatment tumor biopsy (Phase Ⅱ). 5. Have RECIST 1.1-defined measurable lesions. 6. Has a life expectancy of \> 3 months. 7. ECOG performance status 0-1. 8. Adequate marrow, liver and kidney function. 9. Meet the study's specified contraceptive requirements. Exclusion Criteria: 1. Have a second primary malignancy. 2. Patients with primary CNS tumors or CNS metastases with prior local treatment failure. 3. Have received any anti-tumor therapy or participated in other therapeutic clinical trial within 28 days prior to the first dose of study drug. 4. Has undergone major surgery within 28 days prior to the first dose of study drug. 5. Prior anti-tumor therapy-related toxicities have not recovered to protocol-specified grades. 6. Diagnosed with immunodeficiency or received any form of immunosuppressive therapy within 7 days prior to the first dose. 7. Patients with other severe and persistent underlying medical conditions as assessed by the Investigator. 8. Have protocol-defined clinically significant cardiovascular diseases. 9. Prolonged QTcF interval. 10. Have any medical conditions likely to impair digestion and absorption of the investigational product. 11. Patients with poorly managed blood glucose levels and blood pressure. 12. Clinically significant abnormal serum potassium or sodium as judged by the investigator. 13. Have experienced a severe concurrent infection 14 days prior to the first dose of study drug. 14. Confirmed infection with HIV, HBV or HCV. 15. Are currently receiving any other investigation agent. 16. Have received prior CDK2 inhibitors. 17. Patients with known hypersensitivity to the study drug or any of its components. 18. History of allogenic tissue or solid organ transplant. 19. Are unwilling or unable to comply with procedures required in this protocol. 20. Has other severe systemic diseases or for other reasons deemed ineligible for participation in this clinical trial by the investigator.
Conditions Pulmonary Hypertension, Pulmonary Hypert...
Phase Not Applicable
Enrollment 5000
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn about pulmonary hypertension crisis (PHC) - a severe, and often fatal complication - in patients with pulmonary hypertension (PH). The main questions this study aims to answer are: What are the clinical and hemodynamic features of PHC, and what underlying pathophysiological mechanisms cause it to develop? Can these features be used to diagnostic PHC, predict who is at risk of developing it or dying from it, and develop targeted prevention and treatment of PHC? A multi-center registry platform and biobank will be established to enroll and follow up patients with PH. Clinical data, hemodynamic measurements, and biological specimen will be collected. Risk prediction and early warning tools of PHC will be developed.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Primary Outcomes

  • Pulmonary hypertension crisis (From enrollment to 3 years after enrollment)
  • 28 day mortality attributed to pulmonary hypertension crisis (From hospitalization to 28 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-06-17
Completion: 2029-12-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: Not specified
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking Union Medical College Hospital
Principal Investigators:
  • Jinmin Peng, MD (PRINCIPAL_INVESTIGATOR) - Peking Union Medical College Hospital
Contact Information
Study Contact:
Run Dong, MD
861069155036
dongrun5858@foxmail.com
Xianmei Li, MD
+86 20 8382 7812
lixianmei@gdph.org.cn
Guangdong Province People's Hospital
Hailong Dai, MD
+86 0871 63211157
dhlkm@qq.com
Yan'an Affiliated Hospital of Kunming Medical University
Interventions
N/A
Study Locations (4 sites)
Guangdong Province People's Hospital, Guangzhou, Guangdong China
Yan'an Affiliated Hospital of Kunming Medical University, Kunming, Yunnan China
Peking Union Medical College Hospital, Beijing, 100730 China
Shanghai Pulmonary Hospital, Shanghai, China
Eligibility Criteria
Inclusion Criteria: * Pulmonary hypertension confirmed by mean pulmonary arterial pressure (mPAP) over 20 mmHg measured by right heart catheter * At least once per year of follow-up data collection record Exclusion Criteria: * Patients with missing baseline or follow-up data * Complicated by other diseases with significant influence on survival, such as acute coronary syndrome, malignancy, etc. * Complicated by other diseases with significant influence on hemodynamics, such as sepsis, acute left heart failure, and acute pulmonary embolism, etc. * Receiving medications with significant influence on hemodynamics
Conditions Breast Neoplasms, Lung Neoplasms, Urolog...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

BEACON (Benchmarking AI for Clinical Oncology decisioNmaking) is a prospective, multicentre, comparative, blinded, non-interventional benchmark evaluating the treatment recommendations of five frontier large language models (LLMs) against the recommendations of multidisciplinary tumour boards (RCP) in oncology treatment planning. One hundred standardised synthetic cases (20 per localisation, across breast, lung, urological, digestive and gynaecological cancers) are submitted as identical structured input to two independent tumour boards per localisation and to five frontier LLMs. Each recommendation - human or model - is decomposed into five predefined decision domains (intent, surgery, radiotherapy, systemic therapy, work-up and biomarkers) and scored 0/1/2 for concordance against a two-tier reference: the consensus of the two tumour boards, complemented by an a priori locked guideline matrix (ESMO, NCCN). The primary endpoint is domain-level concordance between LLM and RCP consensus, expressed as a linearly weighted Cohen's kappa. A co-primary safety endpoint captures the proportion of recommendations carrying serious harm potential, because concordance alone can conceal dangerous errors. Because expert boards may disagree with one another on identical cases, model performance is always interpreted against the human consensus. BEACON is designed as reusable, openly licensed, pre-registered infrastructure: all synthetic cases, evaluation rubrics, the locked guideline matrix, scoring algorithms and verbatim prompts are released for full reproducibility.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Multidisciplinary tumour boards — Two independent tumour boards per localisation (10 boards in total) issue a categorical recommendation for every synthetic case. Where both boards agree, their consensus defines the reference standard; where they differ, the case-domain is classified as EQUIPOISE and analysed separately.
  • Other: Frontier large language models — Five frontier LLMs (GPT-5.6, Claude Fable 5, Gemini 3.1 Pro, DeepSeek V4 Pro, Llama 4 Maverick) each receive the identical structured input for every case, three times in independent sessions, under locked prompts, versions and settings.

Primary Outcomes

  • Domain-level performance between LLM recommendations and the locked guidelines. (Assessed once at central scoring, after data collection (~October 2026))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-01
Completion: 2026-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Contact Information
Study Contact:
Jean-Emmanuel Bibault, MD PhD
01 56 09 34 06
jean-emmanuel.bibault@aphp.fr
Jérôme Lambert, MD PhD
0142499742
jerome.lambert@u-paris.fr
Jean-Emmanuel Bibault, MD PhD
01 56 09 28 34
jean-emmanuel.bibault@aphp.fr
Hopital Européen Georges Pompidou
Interventions
  • Other: Multidisciplinary tumour boards — Two independent tumour boards per localisation (10 boards in total) issue a categorical recommendation for every synthetic case. Where both boards agree, their consensus defines the reference standard; where they differ, the case-domain is classified as EQUIPOISE and analysed separately.
  • Other: Frontier large language models — Five frontier LLMs (GPT-5.6, Claude Fable 5, Gemini 3.1 Pro, DeepSeek V4 Pro, Llama 4 Maverick) each receive the identical structured input for every case, three times in independent sessions, under locked prompts, versions and settings.
Study Locations (1 sites)
Hopital Européen Georges Pompidou, Paris, France
Eligibility Criteria
Inclusion Criteria: * Synthetic oncology case within one of the five predefined localisations (breast, lung, urological, digestive, gynaecological). * Complete structured schema: UICC 8th-edition stage, biomarkers, ECOG performance status, comorbidities and a standardised clinical question. * A clinically answerable treatment-planning question that is mappable to the locked guideline matrix. Exclusion Criteria: * Case outside the five predefined localisations. * Incomplete, internally inconsistent or ambiguous schema. * Duplicate or near-duplicate of an existing case in the set. * Question not resolvable by current guidelines.
Conditions Major Depression Moderate, Major Depress...
Phase Not Applicable
Enrollment 62
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in patients diagnosed with Major Depressive Disorder who are resistant to at least two antidepressant treatments, using microstate analysis derived from resting-state electroencephalography (EEG) recordings. Within this scope, EEG recordings obtained before and after ECT will be compared to determine the relationships between changes in microstate parameters and inflammatory marker levels, clinical variables, and psychometric scale scores reflecting clinical improvement. Peripheral blood samples collected from the same patient group will be analyzed for complete blood count parameters as well as levels of interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), soluble glycoprotein 130 (sgp-130), soluble interleukin-6 receptor (sIL-6R), interferon gamma-induced protein 10 kDa (IP-10), and C-reactive protein (CRP). In addition, inflammatory indices, including the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Monocyte-to-Lymphocyte Ratio (MLR), will be calculated. The association between baseline levels of these biomarkers and treatment response will be evaluated. Moreover, changes in biomarker levels following ECT will be statistically examined in relation to clinical scale scores and EEG microstate parameters. Although microstate analysis and inflammatory biomarkers have each been extensively investigated in psychiatric disorders, studies evaluating these two biomarkers together, particularly with the inclusion of healthy control participants, remain limited. In this regard, the present study aims to evaluate the effects of ECT on patients with treatment-resistant depression using objective neurophysiological indicators, to contribute to the understanding of the pathophysiology of depression at the level of brain networks, and to provide a scientific basis for the development of personalized treatment approaches in the future.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Device: Electroconvulsive Therapy — ECT will be administered using the Thymatron System IV Integrated ECT Device under general anesthesia, in accordance with standard clinical protocols. Treatments will be delivered using bilateral electrode placement with brief-pulse square-wave stimulation, and if side effects are seen, right unilateral electrode placement will be applied. The duration of treatment, number of sessions, and stimulation parameters will be determined according to each patient's clinical condition.

Primary Outcomes

  • Clinical Response and Remission Assessed by the Montgomery-Åsberg Depression Rating Scale (These assessments will be repeated within 1 week before ECT starts and at 14+6 days and 8 weeks + 6 days after ECT cessation.)
  • Clinical Response Assessed by Hamilton Depression Rating Scale (These assessments will be repeated within 1 week before ECT starts and at 14+6 days and 8 weeks + 6 days after ECT cessation.)
  • EEG Microstate Duration (These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.)
  • EEG Microstate Occurrence (These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.)
  • EEG Microstate Coverage (These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.)
  • EEG Microstate Transition Probability (These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-01
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 62 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istanbul University - Cerrahpasa
Principal Investigators:
  • Alperen Kılıc (STUDY_DIRECTOR) - Associate Professor
  • Burc Cagrı Poyraz, Professor (STUDY_DIRECTOR) - Istanbul University - Cerrahpasa
Contact Information
Study Contact:
Zeynep Özge Dagoglu Sarac, Dr
+905365942469
zod395@gmail.com
Yusuf Cicek, Dr
+905349624762
yusuf.cicek@iuc.edu.tr
Ahmet Torun, Dr
+905526125942
dr.ahmettorun@gmail.com
İstanbul University- Cerrahpasa, Cerrahpasa Medicine Faculty, Psychiatry Department
Interventions
  • Device: Electroconvulsive Therapy — ECT will be administered using the Thymatron System IV Integrated ECT Device under general anesthesia, in accordance with standard clinical protocols. Treatments will be delivered using bilateral electrode placement with brief-pulse square-wave stimulation, and if side effects are seen, right unilateral electrode placement will be applied. The duration of treatment, number of sessions, and stimulation parameters will be determined according to each patient's clinical condition.
Study Locations (1 sites)
İstanbul University- Cerrahpasa, Cerrahpasa Medicine Faculty, Psychiatry Department, Istanbul, Bakırköy Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: Patient Group * Age 18-60 years * Diagnosis of Major Depressive Disorder, current major depressive episode, according to DSM-5 criteria. * Clinical indication for electroconvulsive therapy (ECT). * Ability to provide written informed consent. * Willingness to participate in the study. Healthy Control Group: * Age ≥55 years. * No current psychiatric disorder. * No known neurological disorder. * Good general physical health. * No current use of medications known to affect EEG activity or inflammatory biomarkers significantly. * Ability to provide written informed consent. * Willingness to participate in the study. Exclusion Criteria: * Primary neurological disorders (e.g., dementia or traumatic brain injury). * Schizophrenia or other psychotic disorders. * Bipolar disorder diagnosis, * Intracranial space-occupying lesions. * Increased intracranial pressure. * Myocardial infarction within the previous 3 months. * Cerebrovascular disease within the previous month. * Unstable cerebral aneurysm. * Pheochromocytoma. * Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within the previous month. * Cognitive impairment severe enough to prevent adequate cooperation during EEG recording. * Current alcohol or substance use disorder. * Active infectious disease. * Autoimmune or chronic inflammatory disorders. * Current use of systemic corticosteroids, immunosuppressive agents, or other medications known to affect inflammatory biomarkers significantly.
Conditions Diabete Type 2, Aerobic Exercise, Walkin...
Phase NA
Enrollment 34
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to compare the effects of an 8-week supervised downhill walking training program, prescribed based on the 6-minute walk test, on functional capacity, peripheral muscle strength, and cardiovascular responses in individuals with type 2 diabetes mellitus, as compared to a level walking training program. Participants who agree to take part in the study will be randomly assigned to either the downhill or the level-ground walking group. Both groups will undergo a 6-minute walk test (6MWT) at the beginning of the study, and participants will then undergo an 8-week walking training program-conducted twice a week on a treadmill under the supervision of a physical therapist-in which their walking speed is determined based on their average speed during the 6MWT and gradually increased, with the duration of the sessions also being extended. Participants will do the following: * They will participate in walking training sessions at a center twice a week for 8 weeks, under the supervision of a physical therapist. * Once a week for 8 weeks, they will walk the same distance they walked with their supervisor that week as a homework assignment. * They will come to the facility where they conducted their exercise sessions for evaluations at the beginning of the program and after the 8th week.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Downhill Aerobic Walking Training — This involves performing a progressive aerobic exercise program-prescribed based on the results of a 6-minute walk test-twice a week for 8 weeks, at a constant 10-degree downhill, under the supervision of a physical therapist.
  • Other: Level Aerobic Walking Training — This involves performing a progressive aerobic exercise program-prescribed based on the results of a 6-minute walk test-twice a week for 8 weeks, at a constant 0-degree (i.e., level) slope, under the supervision of a physical therapist.
  • Other: Home exercise session — It involves assigning the distance walked during that week's exercise session-conducted under the supervision of a physical therapist-as homework to be walked at home on one day of the same week.

Primary Outcomes

  • 6-Minute Walk Test (6MWT) (From baseline to the end of treatment at 8 weeks)
  • Measurement of Peripheral Muscle Strength (From baseline to the end of treatment at 8 weeks)
  • Heart Rate Variability (HRV) - Root Mean Square of Successive Differences (RMSSD) (From baseline to the end of treatment at 8 weeks)
  • Heart Rate Variability (HRV) - Standard Deviation of NN Intervals (SDNN) (From baseline to the end of treatment at 8 weeks)
  • Heart Rate Variability (HRV) - Mean RR Interval (From baseline to the end of treatment at 8 weeks)
  • Heart Rate Variability (HRV) - LF/HF Ratio (From baseline to the end of treatment at 8 weeks)
  • Fatigue Severity Scale (FSS) (From baseline to the end of treatment at 8 weeks)
  • Blood Test Results: Glycated Hemoglobin (HbA1c) (From baseline to the end of treatment at 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-01
Completion: 2027-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 34 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Acibadem University
Collaborators: Bezmialem Vakif University
Contact Information
Study Contact:
Meryem Bektaş Karakuş
+90216 500 41 95
meryem.bektas@acibadem.edu.tr
Yasin Baki Baydaş, M.D.
+90216 251 65 65
ybaydas@bezmialem.edu.tr
Bezmialem Vakıf University Dragos Hospital
Interventions
  • Other: Downhill Aerobic Walking Training — This involves performing a progressive aerobic exercise program-prescribed based on the results of a 6-minute walk test-twice a week for 8 weeks, at a constant 10-degree downhill, under the supervision of a physical therapist.
  • Other: Level Aerobic Walking Training — This involves performing a progressive aerobic exercise program-prescribed based on the results of a 6-minute walk test-twice a week for 8 weeks, at a constant 0-degree (i.e., level) slope, under the supervision of a physical therapist.
  • Other: Home exercise session — It involves assigning the distance walked during that week's exercise session-conducted under the supervision of a physical therapist-as homework to be walked at home on one day of the same week.
Study Locations (1 sites)
Bezmialem Vakıf University Dragos Hospital, Istanbul, Maltepe Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Have been diagnosed with Type 2 diabetes mellitus according to the American Diabetes Association (ADA) diagnostic criteria * Be able to walk independently and be physically capable of walking on a treadmill * Have no acute cardiovascular, neurological, or orthopedic conditions that would prevent participation in the exercise program * No major changes to antidiabetic or cardiometabolic treatments within the last 3 months * To be under regular follow-up and in a stable clinical condition * To have been informed about the study and to provide written informed consent Exclusion Criteria: * Patients with severe peripheral neuropathy or a lack of protective sensation * Lower extremity amputation * Diabetic foot ulcer or the presence of severe skin lesions that impair walking * Proliferative diabetic retinopathy or advanced retinopathy that could pose a risk of complications during exercise * Severe diabetic nephropathy (eGFR \<30 mL/min/1.73 m² or macroalbuminuria \>300 mg/g) * Uncontrolled hypertension (systolic blood pressure \>200 mmHg and/or diastolic blood pressure \>110 mmHg) * Fasting blood glucose level \>250 mg/dL with signs of ketosis * Unstable angina pectoris, a history of myocardial infarction within the past 6 months, or a history of clinically significant severe arrhythmia * Advanced heart failure (NYHA Class III-IV) * Having a chronic respiratory disease * Having participated in a regular exercise, sports, or physical therapy program within the past 6 months
Conditions Depression - Major Depressive Disorder
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to learn whether combining repetitive transcranial magnetic stimulation (rTMS) with a computerized behavioral intervention (imagery cognitive bias modification, CBM-I) reduces negative interpretation bias and mild-to-moderate depressive symptoms. The study will also examine neural changes in the dorsolateral prefrontal cortex (DLPFC) and whether timing of interventions affects outcomes. The main questions it aims to answer are: Does active TMS reduce negative interpretation bias and depressive symptoms more than sham TMS? Is delivering CBM-I concurrently with TMS more effective than delivering it consecutively (separate sessions) at reducing negative bias and depressive symptoms? Do combined rTMS + CBM-I approaches produce greater neural changes and improved cognitive control over self-referential interpretation than controls? Researchers will compare active TMS versus sham TMS, and concurrent versus consecutive delivery of CBM-I, to test effects on negative bias and depressive symptoms. Participants will: Receive either active rTMS or sham TMS targeting the DLPFC Complete imagery CBM-I sessions either concurrently with TMS or in separate (consecutive) sessions Undergo assessments of negative interpretation bias, depressive symptoms, and neural measures before and after the intervention

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: TMS — The rTMS group will receive 10 Hz stimulation to the left DLPFC at an intensity of 120% of the resting motor threshold of the right abductor pollicis brevis (APB) muscle with 4 sec trains and 11 sec intertrain intervals for 3000 pulses.Specifically in our study, we combine both intervention, but applying them concurrently and consecutively between groups.
  • Behavioral: Cognitive Bias Modification — Imagery CBM-I focuses on 2 cognitive aspects, mental imagery and interpretation. Participants will be presented with scenarios in which they have to imagine themselves to be in and practice constructing positive endings or interpretations for them.
  • Device: Sham TMS — The TMS coil will be rotated 90 degrees, and will not be delivering active stimulation to the participant. The intensity will be set to 30 and the TMS device will be active, generating enough sound effect but no real stimulation for sham control.

Primary Outcomes

  • Cognitive Bias ("From enrollment to the end of treatment at 4 weeks")
  • Depressive Symptoms ("From enrollment to the end of treatment at 4 weeks")
  • Resting State functional MRI ("From enrollment to the end of treatment at 4 weeks")
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-24
Completion: 2028-12
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Hong Kong
Contact Information
Study Contact:
Richard Liu Mr. Liu
+85290971398
richliu18@connect.hku.hk
Richard Mr. Liu
+85290971398
richliu18@connect.hku.hk
InnoCentre of Clinical Neuropsychology, The University of Hong Kong
Interventions
  • Device: TMS — The rTMS group will receive 10 Hz stimulation to the left DLPFC at an intensity of 120% of the resting motor threshold of the right abductor pollicis brevis (APB) muscle with 4 sec trains and 11 sec intertrain intervals for 3000 pulses.Specifically in our study, we combine both intervention, but applying them concurrently and consecutively between groups.
  • Behavioral: Cognitive Bias Modification — Imagery CBM-I focuses on 2 cognitive aspects, mental imagery and interpretation. Participants will be presented with scenarios in which they have to imagine themselves to be in and practice constructing positive endings or interpretations for them.
  • Device: Sham TMS — The TMS coil will be rotated 90 degrees, and will not be delivering active stimulation to the participant. The intensity will be set to 30 and the TMS device will be active, generating enough sound effect but no real stimulation for sham control.
Study Locations (1 sites)
InnoCentre of Clinical Neuropsychology, The University of Hong Kong, Quarry Bay, Hong Kong Island Hong Kong
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or above * Right-handed * Normal or corrected hearing and vision * Obtained primary education or above * Able to fluently read and understand Chinese * Beck's Depression Inventory-II (BDI-II) score ranging from 14-28 Exclusion Criteria: * History of severe physical disease, brain organic diseases, and neurological disorders (e.g., dementia, brain injury, stroke, epilepsy, Parkinson's disease) * History of substance use/ dependence/ withdrawal * Participants with intellectual disability based on IQ scores * Participants with contraindications for rTMS such as foreign metal bodies, implant devices (cochlear implants) or history (personal or family) of seizure * Participants who are not suitable to be scanned by magnetic resonance imaging (MRI) machine (e.g., claustrophobic, pregnant, metal in the body, hearing aids)
Conditions Asthma (Diagnosis)
Phase PHASE2
Enrollment 264
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: KT-621 — Oral drug

Primary Outcomes

  • Incidence of treatment-emergent adverse events (TEAEs) (From baseline through Week 52)
  • Incidence of treatment-emergent serious adverse events (SAEs) (From baseline through Week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-07
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 264 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kymera Therapeutics, Inc.
Contact Information
Study Contact:
Kymera Medical Director
857-285-5300
clinicaltrials@kymeratx.com
Interventions
  • Drug: KT-621 — Oral drug
Study Locations (1 sites)
Kymera Investigative Site, Tampa, Florida 33607 United States
Eligibility Criteria
Inclusion Criteria: * Must have completed all visits of the parent study, per its protocol, up to the end of treatment (EoT) visit. * Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol. * Must agree to contraceptive requirements in compliance with the clinical study and local requirements. Exclusion Criteria: * Must not have experienced any clinically significant change in health status during the parent study, which, in the opinion of the Investigator, would interfere with participant safety, study evaluations, or compliance with study procedures; or otherwise make the participant unsuitable for participation in this study. * Must not have developed an AE during the parent study, that in the opinion of the Investigator or of the Sponsor's Medical Monitor, could indicate that continued treatment may present an unreasonable risk for the participant. * Must not have met permanent discontinuation criteria and/or permanently discontinued study treatment for any reason during the parent study. * Must not be a member of the Sponsor or site's investigational team or their immediate family. * Must not be unsuitable to enter the study for any other reason, as judged by the Investigator, including potential risk of noncompliance to study procedures.
Conditions Post Operative Delirium, Cognitive Impai...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will examine whether noninvasive, transcutaneous vagal nerve stimulation (tcVNS) can help restore consciousness in patients in the operating room and the Post Anesthesia Care Unit (PACU). The study will also investigate if tcVNS can expedite discharge from the PACU and examine whether tcVNS administerd in the PACU helps reduce delirium and depression after surgery. The study will also evaluate whether tcVNS speeds cognitive recovery from emergence of anesthesia and surgery.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Transcutaneous vagal nerve stimulation — The tcVNS device utilized in this study is not an implanted device, but rather is solely operated outside of the body by affixing it around the patient's ear. The device delivers stimulation of the vagus nerve at designated intensity, interval, and frequency.
  • Device: Sham (No Treatment) — The stimulator is flipped upside down so that the participant does not receive stimulation of the vagal nerve.

Primary Outcomes

  • Aim 1: Primary Endpoint 1: Determine if administering auricular tcVNS enhances the speed of recovery of anesthesia. (24 Hours)
  • Aim1:Primary Endpoint 2 : Richmond Agitation Sedation Scale (RASS Score) (1 Hour)
  • Aim 2: Primary Endpoint 1: Post Anesthesia Care Unit Discharge (PACU) (3 Hours)
  • Aim 2: Primary Endpoint 2: Discharge from Hospital (From PACU discharge (average of two hours post-surgical end time) to study completion (average of two days))
  • Aim 3: Primary Endpoint 1: Post Anesthesia Care Unit delirium (From PACU arrival to one hour post-PACU arrival)
  • Aim 3: Primary Endpoint 1a: Post Anesthesia Care Delirium (30 Days after discharge)
  • Aim3:Primary Endpoint 1b: PHQ-9 (30 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-23
Completion: 2029-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Northwestern University
Principal Investigators:
  • Charles Hogue, MD (PRINCIPAL_INVESTIGATOR) - Northwestern University
Contact Information
Study Contact:
Jordan Wood, BS
3126950915
jordan.wood1@northwestern.edu
Jordan Wood, BS
312-695-0915
jordan.wood1@northwestern.edu
Northwestern University Feinberg School of Medicine
Bin Zhang, MS
312-695-7771
bin.zhang1@northwestern.edu
Northwestern University Feinberg School of Medicine
Interventions
  • Device: Transcutaneous vagal nerve stimulation — The tcVNS device utilized in this study is not an implanted device, but rather is solely operated outside of the body by affixing it around the patient's ear. The device delivers stimulation of the vagus nerve at designated intensity, interval, and frequency.
  • Device: Sham (No Treatment) — The stimulator is flipped upside down so that the participant does not receive stimulation of the vagal nerve.
Study Locations (1 sites)
Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611 United States
Eligibility Criteria
Inclusion Criteria: 1. Aged \> 18 years of age 2. Patients undergoing lumbar surgery for degenerative disc disease or spinal stenosis involving two or more levels 3. Montreal Cognitive Assessment (MoCA) score ≥ 18 - accept mild 4. Ability to use a keyboard 5. Able to understand and communicate in English 6. Be able to consent independently 7. Women of child-bearing age must be comfortable confirming a negative pregnancy prior to participating in the study. 8. Must not be involved in any other research intervention study testing neurobehavioral functioning Exclusion Criteria: 1. Age \< 18 years of age 2. History of vagotomy (cutting the vagus nerve) 3. History of bradycardia, heart block, prolonged QT syndrome, brugada syndrome, heart failure with ejection fraction less than 35% and/or New York Heart Association symptoms 4. MoCA \< 18 5. History of seizure disorder or intracranial hemorrhage 6. Patients with carotid stenosis 7. Patients with aneurysms 8. Other neurological diagnoses or a diagnosis of severe psychiatric disorder (e.g., psychosis) or a reported childhood learning disability 9. Pregnancy, breastfeeding 10. Active addiction history 11. ECG adhesive allergy 12. Severe aphasia, preventing subject from understanding the protocol and giving written consent 13. Patients will be excluded postoperatively if there is neck swelling at the proposed site of left tcVNS.
Conditions Elevated Blood Pressure, Hypertension
Phase PHASE1
Enrollment 64
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacokinetics, and pharmacodynamics of HJB647 following single dose administration in Japanese healthy participants with elevated blood pressure and multiple dose administration with up titration in Japanese patients with hypertension, to support future clinical development of HJB647

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: HJB647 — HJB647 oral capsule
  • Drug: Placebo — Matching oral placebo

Primary Outcomes

  • Part 1: Cmax (Part 1 on Day 1)
  • Part 1: Tmax (Part 1 on Day 1)
  • Part 1: AUClast (Part 1 on Day 1)
  • Part 1: AUCinf (Part 1 on Day 1)
  • Part 1: T1/2 (Part 1 on Day 1)
  • Part 2: Number of participants with AEs (Up to 51 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-07-02
Completion: 2026-12-25
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Principal Investigators:
  • Novartis Pharmaceuticals (STUDY_DIRECTOR) - Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
+81337978748
novartis.email@novartis.com
Novartis Pharmaceuticals
Interventions
  • Drug: HJB647 — HJB647 oral capsule
  • Drug: Placebo — Matching oral placebo
Study Locations (1 sites)
Novartis Investigative Site, Sumida Ku, Tokyo 1300004 Japan
Eligibility Criteria
Inclusion Criteria: * Japanese healthy participants with elevated blood pressure (Part 1) and patients with mild-to-moderate hypertension (Part 2) * Age: 18 to 55 years (Part 1) and 18 to 60 years (Part 2) * Body weight: * Male: ≥ 50.0 kg * Female: ≥ 45.0 kg * Body Mass Index (BMI): 18.0 to 30.0 kg/m² * Axillary body temperature: 35.0-37.5 °C * Heart rate: 50-90 bpm * Blood pressure criteria are as follows: * Part 1: Healthy Participants with Elevated Blood Pressure Screening: Systolic Blood Pressure (SBP): 120 ≤ SBP ≤ 139 mmHg; Diastolic Blood Pressure (DBP): 60 ≤ DBP ≤ 94 mmHg Baseline (Day -1): SBP: 120 ≤ SBP ≤ 179 mmHg; DBP: 60 ≤ DBP ≤ 109 mmHg * Part 2: Patients with Hypertension Screening and Baseline (Day -1): SBP: 140 ≤ SBP ≤ 179 mmHg; DBP: 60 ≤ DBP ≤ 109 mmHg Exclusion Criteria: * Significant illness, including infectious diseases that have not resolved within 30 days prior to baseline * History or current diagnosis of ECG or cardiac abnormalities indicating significant risk of safety for participants such as: * Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker. * History of familial long QT syndrome or known family history of Torsades de Pointes * Resting QT interval corrected by Fridericia's formula (QTcF) ≥ 450 msec (male) or ≥ 460 msec (female) at screening * At screening, hypokalemia or hypomagnesemia defined as potassium or magnesium values below the LLN on repeat measurement, or laboratory abnormalities indicating hypothyroidism, as determined at the discretion of the investigator * HbA1c ≥ 7.0% or LDL cholesterol ≥ 180 mg/dL or triglycerides ≥ 250 mg/dL * Use of any prescription drugs or herbal supplements within 4 weeks prior to initial dosing, and/or OTC medication or dietary supplements (vitamins included) within 2 weeks prior to initial dosing * Women of childbearing potential Other protocol-defined inclusion/exclusion criteria may apply
Conditions Preeclampsia
Phase PHASE4
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized clinical trial is to compare the effects of two doses of aspirin, 75 mg and 150 mg, in pregnant women who are at high risk of developing preeclampsia. The main question the study aims to answer is: 1. Does taking 150 mg of aspirin reduce the occurrence of preeclampsia more effectively than taking 75 mg of aspirin in pregnant women at high risk of preeclampsia? 2. Are there differences in stillbirth and newborn birth weight between the two aspirin doses? The study will include 224 pregnant women aged 18-45 years who are between 11 and 14 weeks of pregnancy and are identified as being at high risk for preeclampsia. Participants will be randomly assigned to one of two groups. * Participants in the low-dose group will take 75 mg of aspirin once daily at bedtime. * Participants in the high-dose group will take 150 mg of aspirin once daily at bedtime. Participants will continue their assigned aspirin dose until 36 weeks of pregnancy and will be followed every 2 weeks until delivery. The study will record whether participants develop preeclampsia and whether stillbirth occurs. The birth weight of each newborn will also be measured within 3 hours of birth. The study hypothesis is that 150 mg of aspirin will result in a lower incidence of preeclampsia than 75 mg of aspirin in pregnant women at high risk of preeclampsia.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Drug: Aspirin — Aspirin 75 mg administered orally once daily at bedtime from 11-14 weeks of pregnancy until 36 weeks of pregnancy.
  • Drug: Aspirin — Aspirin 150 mg administered orally once daily at bedtime from 11-14 weeks of pregnancy until 36 weeks of pregnancy

Primary Outcomes

  • Incidence of Preeclampsia (From enrollment at 11-14 weeks of pregnancy until delivery, up to 36 weeks of gestation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-05-12
Completion: 2026-11-11
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medicare Hospital (Pvt) Limited
Principal Investigators:
  • Samee A Professor, FRCOG (STUDY_CHAIR) - Medicare Hospital (Pvt) Ltd.
Contact Information
Study Contact:
Fiza A Principal Investigator, MBBS
+92 336 6005416
fiza.arshad66@gmail.com
Samee A Professor, FRCOG
+92 300 8637070
sameeakhtar54@gmail.com
Fiza A Principal Investigator, MBBS
+92 336 6005416
fiza.arshad66@gmail.com
Medicare Hospital (Pvt) Ltd.
Interventions
  • Drug: Aspirin — Aspirin 75 mg administered orally once daily at bedtime from 11-14 weeks of pregnancy until 36 weeks of pregnancy.
  • Drug: Aspirin — Aspirin 150 mg administered orally once daily at bedtime from 11-14 weeks of pregnancy until 36 weeks of pregnancy
Study Locations (1 sites)
Medicare Hospital (Pvt) Ltd., Multan, Punjab Province 60000 Pakistan
Eligibility Criteria
Inclusion Criteria: * Gestational age 11-14 weeks * High risk of preeclampsia Exclusion Criteria: * Active gastritis * Abnormal coagulation profile (INR \> 1.5) * Renal disease * Platelet count \< 150,000/mm\^3 * Fetal malformations * Vaginal bleeding
Conditions Breast Cancer, Exercise
Phase NA
Enrollment 78
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

All patients undergoing mastectomy for breast cancer should be offered the option of reconstructive surgery. The Deep Inferior Epigastric Perforator Flap or DIEP reconstruction as it is commonly referred to, is becoming the favoured reconstruction by both patients and surgeons as it gives a great cosmetic outcome as well as being a good option for patients who may have to undergo radiotherapy treatment after their surgery. Exercise has been demonstrated in previous research to improve tolerance of treatment (particularly chemotherapy), post operative fatigue and the overall quality of life in patients undergoing cancer treatment. Furthermore, it has shown to improve survival in patients who are being treated for breast cancer. The investigators are undertaking this study to investigate whether a structured exercise programme will improve patients fitness after surgery and ultimately improve their recovery after their reconstructive surgery. To do this, half of the people taking part will be undertaking a structured exercise programme and the other half will not and will be assessing which group recover better after their surgery. Currently, no breast reconstruction patients in Ireland are receiving a formal "exercise prescription" after their surgery so will be looking to see if this helps people recover better before it is made standard care for every breast patient in Ireland.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Structured individualised 12-week post operative exercise programme — Structured individualised 12-week post operative exercise programme based on ACSM oncology guidelines, incorporating aerobic, resistance and flexibility training delivered in person or via zoom.

Primary Outcomes

  • Cardiorespiratory Fitness (Measured at baseline (recruitment), 6 months postoperatively and at 1 year postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-01
Completion: 2028-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 78 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Royal College of Surgeons, Ireland
Contact Information
Study Contact:
Arnold Hill, MB, BCh, BAO, MCh, FRCSI
+35318093000
adkhill@rcsi.com
Aisling Hegarty, PhD
018093000
Aislinghegarty@rcsi.ie
Interventions
  • Behavioral: Structured individualised 12-week post operative exercise programme — Structured individualised 12-week post operative exercise programme based on ACSM oncology guidelines, incorporating aerobic, resistance and flexibility training delivered in person or via zoom.
Study Locations (1 sites)
Beaumont RCSI Cancer Centre, Beaumont, Dublin D09V2N0 Ireland
Eligibility Criteria
Inclusion Criteria: 1. Women aged 18 years and older 2. Candidates who have already been selected to undergo mastectomy and reconstruction by the breast MDT for the following indications: 1. Genetic mutation carriers undergoing risk-reducing mastectomy. 2. Ductal carcinoma in situ (DCIS) requiring mastectomy. 3. Early invasive breast cancer requiring mastectomy. 4. The tumour must not have skin involvement and no evidence of invasive disease within 1cm of skin, nipple or pectoralis major muscle (as proven on MRI). 3. Candidates for breast reconstruction with DIEP. 4. Fluent in English 5. Fit for general anaesthetic Signed informed consent form Exclusion Criteria: 1. Advanced breast cancer with skin involvement. 2. Undergoing bilateral DIEP reconstruction or other forms of breast reconstruction (e.g., TRAM, implant-based, LD flap). 3. Pregnancy 4. Lactation Patients with insufficient English to sign an informed consent (i.e. interpreter required).